Literature DB >> 22308455

Three differentiation states risk-stratify bladder cancer into distinct subtypes.

Jens-Peter Volkmer1, Debashis Sahoo, Robert K Chin, Philip Levy Ho, Chad Tang, Antonina V Kurtova, Stephen B Willingham, Senthil K Pazhanisamy, Humberto Contreras-Trujillo, Theresa A Storm, Yair Lotan, Andrew H Beck, Benjamin I Chung, Ash A Alizadeh, Guilherme Godoy, Seth P Lerner, Matt van de Rijn, Linda D Shortliffe, Irving L Weissman, Keith S Chan.   

Abstract

Current clinical judgment in bladder cancer (BC) relies primarily on pathological stage and grade. We investigated whether a molecular classification of tumor cell differentiation, based on a developmental biology approach, can provide additional prognostic information. Exploiting large preexisting gene-expression databases, we developed a biologically supervised computational model to predict markers that correspond with BC differentiation. To provide mechanistic insight, we assessed relative tumorigenicity and differentiation potential via xenotransplantation. We then correlated the prognostic utility of the identified markers to outcomes within gene expression and formalin-fixed paraffin-embedded (FFPE) tissue datasets. Our data indicate that BC can be subclassified into three subtypes, on the basis of their differentiation states: basal, intermediate, and differentiated, where only the most primitive tumor cell subpopulation within each subtype is capable of generating xenograft tumors and recapitulating downstream populations. We found that keratin 14 (KRT14) marks the most primitive differentiation state that precedes KRT5 and KRT20 expression. Furthermore, KRT14 expression is consistently associated with worse prognosis in both univariate and multivariate analyses. We identify here three distinct BC subtypes on the basis of their differentiation states, each harboring a unique tumor-initiating population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22308455      PMCID: PMC3277552          DOI: 10.1073/pnas.1120605109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  MiDReG: a method of mining developmentally regulated genes using Boolean implications.

Authors:  Debashis Sahoo; Jun Seita; Deepta Bhattacharya; Matthew A Inlay; Irving L Weissman; Sylvia K Plevritis; David L Dill
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

2.  Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development.

Authors:  Matthew A Inlay; Deepta Bhattacharya; Debashis Sahoo; Thomas Serwold; Jun Seita; Holger Karsunky; Sylvia K Plevritis; David L Dill; Irving L Weissman
Journal:  Genes Dev       Date:  2009-10-15       Impact factor: 11.361

3.  Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer.

Authors:  Yun Su; Qi Qiu; Xingqiao Zhang; Zhengran Jiang; Qixin Leng; Zhenqiu Liu; Sanford A Stass; Feng Jiang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

4.  Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells.

Authors:  Keith Syson Chan; Inigo Espinosa; Mark Chao; David Wong; Laurie Ailles; Max Diehn; Harcharan Gill; Joseph Presti; Howard Y Chang; Matt van de Rijn; Linda Shortliffe; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-04       Impact factor: 11.205

Review 5.  Cancer stem cells in bladder cancer: a revisited and evolving concept.

Authors:  Keith Syson Chan; Jens-Peter Volkmer; Irving Weissman
Journal:  Curr Opin Urol       Date:  2010-09       Impact factor: 2.309

6.  Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

Authors:  David Lindgren; Attila Frigyesi; Sigurdur Gudjonsson; Gottfrid Sjödahl; Christer Hallden; Gunilla Chebil; Srinivas Veerla; Tobias Ryden; Wiking Månsson; Fredrik Liedberg; Mattias Höglund
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

7.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

Authors:  Elgene Lim; François Vaillant; Di Wu; Natasha C Forrest; Bhupinder Pal; Adam H Hart; Marie-Liesse Asselin-Labat; David E Gyorki; Teresa Ward; Audrey Partanen; Frank Feleppa; Lily I Huschtscha; Heather J Thorne; Stephen B Fox; Max Yan; Juliet D French; Melissa A Brown; Gordon K Smyth; Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Med       Date:  2009-08-02       Impact factor: 53.440

8.  Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma.

Authors:  Xiaobing He; Luigi Marchionni; Donna E Hansel; Wayne Yu; Akshay Sood; Jie Yang; Giovanni Parmigiani; William Matsui; David M Berman
Journal:  Stem Cells       Date:  2009-07       Impact factor: 6.277

9.  Boolean implication networks derived from large scale, whole genome microarray datasets.

Authors:  Debashis Sahoo; David L Dill; Andrew J Gentles; Robert Tibshirani; Sylvia K Plevritis
Journal:  Genome Biol       Date:  2008-10-30       Impact factor: 13.583

10.  Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.

Authors:  Wun-Jae Kim; Eun-Jung Kim; Seon-Kyu Kim; Yong-June Kim; Yun-Sok Ha; Pildu Jeong; Min-Ju Kim; Seok-Joong Yun; Keon Myung Lee; Sung-Kwon Moon; Sang-Cheol Lee; Eun-Jong Cha; Suk-Chul Bae
Journal:  Mol Cancer       Date:  2010-01-08       Impact factor: 27.401

View more
  112 in total

1.  Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer.

Authors:  Philip Levy Ho; Erica Julianne Lay; Weiguo Jian; Diana Parra; Keith Syson Chan
Journal:  Cancer Res       Date:  2012-04-24       Impact factor: 12.701

2.  A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors.

Authors:  Garrett M Dancik; Charles R Owens; Kenneth A Iczkowski; Dan Theodorescu
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

3.  Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.

Authors:  Opal L Reddy; Justin M Cates; Lan L Gellert; Henry S Crist; Zhaohai Yang; Hironobu Yamashita; John A Taylor; Joseph A Smith; Sam S Chang; Michael S Cookson; Chaochen You; Daniel A Barocas; Magdalena M Grabowska; Fei Ye; Xue-Ru Wu; Yajun Yi; Robert J Matusik; Klaus H Kaestner; Peter E Clark; David J DeGraff
Journal:  Am J Pathol       Date:  2015-05       Impact factor: 4.307

4.  Stage- and subunit-specific functions of polycomb repressive complex 2 in bladder urothelial formation and regeneration.

Authors:  Chunming Guo; Zarine R Balsara; Warren G Hill; Xue Li
Journal:  Development       Date:  2017-01-03       Impact factor: 6.868

Review 5.  [Molecular tumor board-urothelial cancer].

Authors:  M C Hupe; G Gakis; R Seiler
Journal:  Urologe A       Date:  2019-07       Impact factor: 0.639

Review 6.  Role of Sonic Hedgehog (Shh) Signaling in Bladder Cancer Stemness and Tumorigenesis.

Authors:  Islam S Syed; Akbari Pedram; Walid A Farhat
Journal:  Curr Urol Rep       Date:  2016-02       Impact factor: 3.092

Review 7.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

Review 8.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

9.  Claudin-low bladder tumors are immune infiltrated and actively immune suppressed.

Authors:  Jordan Kardos; Shengjie Chai; Lisle E Mose; Sara R Selitsky; Bhavani Krishnan; Ryoichi Saito; Michael D Iglesia; Matthew I Milowsky; Joel S Parker; William Y Kim; Benjamin G Vincent
Journal:  JCI Insight       Date:  2016-03-17

10.  Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin.

Authors:  Lei Miao; Yuhua Wang; C Michael Lin; Yang Xiong; Naihan Chen; Lu Zhang; William Y Kim; Leaf Huang
Journal:  J Control Release       Date:  2015-08-15       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.